FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1859831320> ?p ?o ?g. }

• W1859831320 endingPage "1524" @default.
• W1859831320 startingPage "1517" @default.
• W1859831320 abstract "PURPOSE: To determine whether the use of a recombinant human granulocyte colony-stimulating factor ([G-CSF] lenogastrim) can increase the chemotherapy dose-intensity (CDI) delivered during consolidation chemotherapy of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: Sixty-seven children with very high-risk ALL were randomized (slow early response to therapy, 55 patients; translocation t(9;22) or t(4;11), 12 patients). Consolidation consisted of six courses of chemotherapy; the first, third, and fifth courses were a combination of high-dose cytarabine, etoposide, and dexamethasone (R3), whereas the second, fourth, and sixth courses included vincristine, prednisone, cyclophosphamide, doxorubicin, and methotrexate (COPADM). G-CSF was given after each course, and the next scheduled course was started as soon as neutrophil count was > 1 × 10 9 /L and platelet count was > 100 × 10 9 /L. CDI was calculated using the interval from day 1 of the first course to hematologic recovery after the fifth course (100% CDI = 105-day interval). RESULTS: CDI was significantly increased in the G-CSF group compared with the non–G-CSF group (mean ± 95% confidence interval, 105 ± 5% v 91 ± 4%; P < .001). This higher intensity was a result of shorter post-R3 intervals in the G-CSF group, whereas the post-COPADM intervals were not statistically reduced. After the R3 courses, the number of days with fever and intravenous antibiotics and duration of hospitalization were significantly decreased by G-CSF, whereas reductions observed after COPADM were not statistically significant. Duration of granulocytopenia was reduced in the G-CSF group, but thrombocytopenia was prolonged, and the number of platelet transfusions was increased. Finally, the 3-year probability of event-free survival was not different between the two groups. CONCLUSION: G-CSF can increase CDI in high-risk childhood ALL. Its effects depend on the chemotherapy regimen given before G-CSF administration. In our study, a higher CDI did not improve disease control." @default.
• W1859831320 created "2016-06-24" @default.
• W1859831320 creator A5000858647 @default.
• W1859831320 creator A5008895675 @default.
• W1859831320 creator A5018536511 @default.
• W1859831320 creator A5023552802 @default.
• W1859831320 creator A5032184750 @default.
• W1859831320 creator A5036667713 @default.
• W1859831320 creator A5037737991 @default.
• W1859831320 creator A5040756049 @default.
• W1859831320 creator A5042197913 @default.
• W1859831320 creator A5042346885 @default.
• W1859831320 creator A5045763298 @default.
• W1859831320 creator A5047925131 @default.
• W1859831320 creator A5054047613 @default.
• W1859831320 creator A5059143263 @default.
• W1859831320 creator A5066679392 @default.
• W1859831320 creator A5075262723 @default.
• W1859831320 creator A5086508678 @default.
• W1859831320 creator A5090367243 @default.
• W1859831320 date "2000-04-07" @default.
• W1859831320 modified "2023-09-27" @default.
• W1859831320 title "Use of Recombinant Human Granulocyte Colony-Stimulating Factor to Increase Chemotherapy Dose-Intensity: A Randomized Trial in Very High-Risk Childhood Acute Lymphoblastic Leukemia" @default.
• W1859831320 cites W1819462601 @default.
• W1859831320 cites W1904793007 @default.
• W1859831320 cites W1918033056 @default.
• W1859831320 cites W1939497674 @default.
• W1859831320 cites W1966547883 @default.
• W1859831320 cites W1976897003 @default.
• W1859831320 cites W1978319003 @default.
• W1859831320 cites W1981428106 @default.
• W1859831320 cites W2041554619 @default.
• W1859831320 cites W2072502760 @default.
• W1859831320 cites W2102050352 @default.
• W1859831320 cites W2147996630 @default.
• W1859831320 cites W2163596966 @default.
• W1859831320 cites W2226233012 @default.
• W1859831320 cites W2326181393 @default.
• W1859831320 cites W2336479938 @default.
• W1859831320 cites W4255803928 @default.
• W1859831320 cites W55367026 @default.
• W1859831320 cites W5946015 @default.
• W1859831320 doi "https://doi.org/10.1200/jco.2000.18.7.1517" @default.
• W1859831320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10735900" @default.
• W1859831320 hasPublicationYear "2000" @default.
• W1859831320 type Work @default.
• W1859831320 sameAs 1859831320 @default.
• W1859831320 citedByCount "47" @default.
• W1859831320 countsByYear W18598313202012 @default.
• W1859831320 countsByYear W18598313202013 @default.
• W1859831320 countsByYear W18598313202014 @default.
• W1859831320 countsByYear W18598313202015 @default.
• W1859831320 countsByYear W18598313202017 @default.
• W1859831320 crossrefType "journal-article" @default.
• W1859831320 hasAuthorship W1859831320A5000858647 @default.
• W1859831320 hasAuthorship W1859831320A5008895675 @default.
• W1859831320 hasAuthorship W1859831320A5018536511 @default.
• W1859831320 hasAuthorship W1859831320A5023552802 @default.
• W1859831320 hasAuthorship W1859831320A5032184750 @default.
• W1859831320 hasAuthorship W1859831320A5036667713 @default.
• W1859831320 hasAuthorship W1859831320A5037737991 @default.
• W1859831320 hasAuthorship W1859831320A5040756049 @default.
• W1859831320 hasAuthorship W1859831320A5042197913 @default.
• W1859831320 hasAuthorship W1859831320A5042346885 @default.
• W1859831320 hasAuthorship W1859831320A5045763298 @default.
• W1859831320 hasAuthorship W1859831320A5047925131 @default.
• W1859831320 hasAuthorship W1859831320A5054047613 @default.
• W1859831320 hasAuthorship W1859831320A5059143263 @default.
• W1859831320 hasAuthorship W1859831320A5066679392 @default.
• W1859831320 hasAuthorship W1859831320A5075262723 @default.
• W1859831320 hasAuthorship W1859831320A5086508678 @default.
• W1859831320 hasAuthorship W1859831320A5090367243 @default.
• W1859831320 hasConcept C126322002 @default.
• W1859831320 hasConcept C141071460 @default.
• W1859831320 hasConcept C2776694085 @default.
• W1859831320 hasConcept C2776755627 @default.
• W1859831320 hasConcept C2777063308 @default.
• W1859831320 hasConcept C2777767877 @default.
• W1859831320 hasConcept C2778041864 @default.
• W1859831320 hasConcept C2778119113 @default.
• W1859831320 hasConcept C2778461978 @default.
• W1859831320 hasConcept C2778720950 @default.
• W1859831320 hasConcept C2779429289 @default.
• W1859831320 hasConcept C2780401358 @default.
• W1859831320 hasConcept C2781107101 @default.
• W1859831320 hasConcept C2909962599 @default.
• W1859831320 hasConcept C44249647 @default.
• W1859831320 hasConcept C71924100 @default.
• W1859831320 hasConcept C74133956 @default.
• W1859831320 hasConcept C90924648 @default.
• W1859831320 hasConceptScore W1859831320C126322002 @default.
• W1859831320 hasConceptScore W1859831320C141071460 @default.
• W1859831320 hasConceptScore W1859831320C2776694085 @default.
• W1859831320 hasConceptScore W1859831320C2776755627 @default.
• W1859831320 hasConceptScore W1859831320C2777063308 @default.
• W1859831320 hasConceptScore W1859831320C2777767877 @default.
• W1859831320 hasConceptScore W1859831320C2778041864 @default.
• W1859831320 hasConceptScore W1859831320C2778119113 @default.

• next